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Red blood cell phenotyping after transfusion: 
an in vitro model
K. Gonsalkorale, C. Vanhecke, and K.G. Badami
Recipient red blood cell (RBC) phenotyping using serologic 
techniques, within 3 months of a transfusion, is considered 
unreliable. We conducted in vitro experiments to determine how 
long recipient RBC phenotyping results would be compromised 
after an allogeneic transfusion. In vitro models were created to 
mimic in vivo posttransfusion ratios of “transfused” RBCs with 
either a single or a double dose of an antigen and “autologous” 
RBCs negative for the corresponding antigen at 10-day intervals 
from day 0 to day 90 in hypothetical recipients with varying 
weights and hematocrits (Hct) receiving varying numbers of 
RBC units. In general, a reliable recipient RBC phenotype was 
possible earlier after transfusion in larger recipients, those with 
higher Hct, and those transfused with fewer RBC units and if the 
transfused units had the antigen of interest in single, rather than 
double, dose. We believe that a reliable RBC phenotype, using 
routine serologic techniques, can often be obtained well before 
3 months after transfusion. Similar studies with other donors, 
antigens, antisera, and methods and in actual patients will be 
useful. Immunohematology 2013;29:93–6.
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Recipient red blood cell (RBC) phenotyping may be useful 
in determining what clinically significant alloantibodies a 
recipient could make by identifying the antigens that the 
recipient lacks. It has been considered difficult to do this 
after transfusion, but it is the regularly transfused patient in 
whom this information is most useful. Alternatives exist—e.g., 
genotyping—but this may not be possible everywhere. We 
used an experimental model to determine how soon after a 
hypothetical “transfusion” an unequivocal “recipient” RBC 
phenotype could be determined using conventional serologic 
methods.
Materials and Methods
In vitro mixtures of RBCs were created to mimic in vivo 
“posttransfusion” ratios of “autologous” to “transfused” RBCs 
at 10-day intervals from day 0 to day 90 after transfusion of 
varying numbers of RBC units in recipients of varying weights 
and with varying degrees of anemia.
In our model, C+, Jk(a+), or K+ RBC units were transfused 
to C–, Jk(a–), or K– recipients, respectively. RBC transfusions 
with a single or double dose of the antigen concerned were 
considered separately. The transfused and autologous RBCs 
used in the experiments came from four healthy blood donors 
or volunteers (blood groups: O, rr, K–k+, Jk[a–b+]; O, R1R1, 
K–k+, Jk[a+b–]; O, R1r, K+k–, Jk[a–b+]; O, R1r, K+k+, Jk[a+b+]) 
whose units were less than 1 week old.
Nominal male recipients weighing 50, 70, or 100 kg, with 
estimated blood volumes (EBV) appropriate to weight, with 
either of two levels of anemia (hematocrit [Hct] 25% or 15%) 
were considered. The EBV was taken as 70 mL/kg, i.e., the 
midpoint of the normal range in either sex (60–80 mL/kg).1 
The volume of autologous RBCs in the recipient was calculated 
from the EBV and Hct. Recipients with Hct of 25 percent were 
considered to have received one, two, or three units of packed 
RBCs and those with Hct of 15 percent, two, three, or four units.
Per the standard specifications for leukocyte-reduced RBC 
units in New Zealand, the average volume of RBC units was 
determined to be 300 mL, the average Hct was 60 percent, 
and posttransfusion RBC recovery (PTR) was 80 percent, 
resulting in an RBC volume per RBC unit transfused of 144 
mL. It was assumed that transfused RBCs survived optimally. 
Thus, the loss of transfused RBCs per day was taken as 1/120 
of the RBC volume transfused on day 0 (144 mL × number of 
RBC units transfused).
For instance, a 50-kg recipient with an EBV of 3500 
mL (70 mL/kg) and Hct of 15 percent might have an RBC 
volume of approximately 525 mL. If such a recipient were to 
be transfused with three RBC units, the volume of transfused 
RBCs on day 0 would be 144 mL × 3 or 432 mL. Assuming 
that 1/120 of the transfused RBCs are destroyed each day, 
surviving transfused RBCs after 10 days would be 396 mL, 
after 20 days would be 363 mL, and so on. Similar calculations 
were done for all nominal recipients. Note that it was assumed 
that the autologous RBC volume stayed constant as a result 
of balanced production and destruction. Posttransfusion 
ratios of autologous to transfused RBCs at different times 
were calculated for all recipients, factoring in recipient weight, 
Hct, and days after transfusion as described previously. These 
are shown in Figure 1 expressed as calculated percentages of 
RBCs in the recipient that are likely to be transfused RBCs.
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The actual volumes of the RBC suspensions—either a 3 
percent or 0.8 percent suspension of the RBC mixture (Ortho 
Biovue and DiaMed-ID, respectively—see later section)—used 
varied, from the one with the highest autologous-to-transfused 
ratio (1750 µL:65.8 µL in the nominal 100-kg patient with an 
Hct of 25%, at day 90 after transfusion of one RBC unit) to 
the one with the lowest autologous-to-transfused ratio (576 
µL:525 µL in the nominal 50-kg patient with an Hct of 15%, 
at day 0 after transfusion of four RBC units). In each case we 
started with the autologous-to-transfused RBC ratio most 
likely to show a clear negative reaction (a score of 0), i.e., a high 
ratio. Then, mixtures with successively lower autologous-to-
transfused RBC ratios were tested until the point at which 
a clear negative reaction was no longer obtainable. The last 
ratio giving a clear negative reaction was taken as the day 
beyond which it was possible to ascertain the autologous, 
antigen-negative RBC phenotype. This was done separately 
for transfused RBCs with a single or double antigen dose.
RBC phenotyping was done using column agglutination 
methods (Ortho BioVue System, Ortho Clinical Diagnostics, 
Raritan, NJ) for C and K and (DiaMed-ID Micro Typing 
System, DiaMed AG, Morat, Switzerland) for Jka. Commercially 
obtained antisera (anti-C and anti-Jka, Lorne Laboratories, 
Reading, UK) were used. The anti-K was incorporated in the 
gel card (Ortho BioVue System, Ortho Clinical Diagnostics). 
Validated New Zealand Blood Service procedures were 
followed. Positive and negative controls were run in parallel 
with test samples.
Results
All four variables studied (recipient weight and Hct, the 
number of antigen-positive RBC units transfused, and the 
dose of the relevant antigens in the transfused units) affected 
which day after transfusion the autologous, antigen-negative 
RBC phenotype could be determined (Table 1).
Fig. 1 Calculated percentage of transfused red blood cells (RBCs) remaining at varying times after transfusion in recipients with different 
values for weight, hematocrit (Hct), and number of RBC units transfused.
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In general, in nominal recipients with an Hct of 25 percent, 
we were able to determine the autologous RBC phenotype 
relatively early after transfusion. This was especially true of 
larger recipients; of those transfused with fewer RBC units; 
and if the RBCs expressed a single, rather than a double, dose 
of the antigen concerned. In nominal recipients with a Hct of 
15 percent weighing 50 or 70 kg, irrespective of the antigen, its 
dose, or the number of RBC units transfused, the autologous, 
antigen-negative phenotype could not be unequivocally 
determined even at day 90 after transfusion. This was 
also largely true for the 100-kg recipient with an Hct of 15 
percent except that, in this case, a clear negative (autologous) 
phenotype could be established in the day 90 sample with two 
transfused RBC units if the C, Jka, or K antigen was present in 
a single dose (Table 1).
Discussion
Recipient RBC phenotyping may be useful in at least three 
situations in recently transfused patients: first, to avoid further 
exposure to clinically significant RBC antigens in those likely 
to require RBC transfusions long-term (ideally such recipients 
should be phenotyped before the first transfusion); second, 
to corroborate alloantibody specificities; and third, to allow 
alloadsorption studies using phenotype-matched RBCs in 
patients with autoimmune hemolytic anemia to be more easily 
performed.
Serologic determination of RBC phenotype in recently 
transfused patients is considered difficult2 and is generally not 
recommended within 3 months of a transfusion.3 Alternatives 
in this situation include using the resistance of RBCs from 
patients with sickle cell disease, relative to transfused RBCs, 
to hypotonic lysis4; autologous reticulocyte phenotyping 
after initial separation in microhematocrit tubes5 or by using 
immunomagnetic6 or color flow cytometric methods7; and 
genotyping using polymerase chain reaction and related 
methods.8 Many such methods are not generally available.
The 3-month period referred to previously does not 
take into account variables such as recipient weight and Hct, 
the number of transfused units, or the antigen dose in the 
transfused units—the effects of all of which were examined in 
this in vitro study. Patient weight determines, to an extent, the 
blood volume, which is the volume of dilution for transfused 
cellular components. If the volume of RBCs transfused is 
high relative to the patient’s volume of dilution and Hct, one 
might expect a relative delay in establishing an unequivocal 
patient RBC phenotype after transfusion. We might also 
expect similar delays in patients with chronic RBC synthesis 
failure or hemolysis as opposed to, say, otherwise well patients 
who are anemic after an acute blood loss in whom it might be 
expected that autologous RBC synthesis would be significantly 
increased after the acute event.
To our knowledge, an in vitro model of this sort has not 
previously been described in the literature. Our experiments 
suggest that, at least for the antigens we considered, a clear 
RBC phenotype can be obtained for some transfusion 
recipients well before 3 months after transfusion, using 
routine serologic methods, although this may not be possible 
in others, for instance, small-sized individuals with low Hct 
given relatively large RBC transfusions (Table 1). We expect 
that similar results will be obtained with other RBC antigens.
Both the Council of Europe and the US Food and Drug 
Administration guidelines9,10 require a PTR of at least 75 
percent 24 hours after transfusion. We assumed a PTR of 80 
percent, which is within the range that might be expected for 
transfused RBCs toward the end of shelf-life,11 and we used 
this figure in our experiments to determine transfused-to-
autologous RBC ratios at various time intervals. Of course, 










Phenotype of transfused RBCs
C+c– C+c+ Jk(a+b–) Jk(a+b+) K+k– K+k+
50 15 4 — — — — — —
50 15 3 — — — — — —
70 15 4 — — — — — —
70 15 3 — — — — — —
100 15 4 — — — — — —
50 15 2 — — — — — —
50 25 3 — — — — — 80
100 15 3 — — — — — —
70 15 2 — — — — — —
70 25 3 — — — — — 40
50 25 2 — — — — — 40
100 15 2 — 90 — 90 — 90
100 25 3 — 80 — 80 — 0
70 25 2 — 80 — 80 90 0
50 25 1 70 40 90 40 90 50
100 25 2 70 40 90 40 50 0
70 25 1 30 0 50 0 10 0
100 25 1 0 0 10 0 0 0
*Calculated number of days after “transfusion” of C+, Jk(a+), or K+ (single 
or double antigen dose) red blood cells (RBCs) when an antigen-negative 
phenotype can be (shaded numbers) or cannot be (dashes) established 
serologically before 3 months after transfusion in an unequivocal recipient, 
with consideration of recipient weight, hematocrit (Hct), and number of RBC 
units “transfused” and with different ratios of antigen-positive (“transfused”) 
and antigen-negative (“autologous”) RBCs corresponding to different 10-day 
periods after transfusion.
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higher recoveries (e.g., approximately 90%) may be obtained 
with fresher units,11 and this would tend to increase the 
proportion of transfused RBCs relative to autologous RBCs 
at various times after transfusion. However, Luten et al.11 
also noted that PTR in transfused patients may be lower than 
in healthy volunteers, which would have the opposite effect, 
i.e., to decrease the proportion of transfused RBCs relative to 
autologous RBCs.
In most patients (again, with the exception of individuals 
with low EBV and low Hct given relatively large RBC 
transfusions), the proportion of antigen-positive, transfused 
RBCs is likely to be small relative to that of autologous RBCs. 
We considered only unequivocal negative results as indicative 
of the true autologous, antigen-negative RBC phenotype. 
However, in the context of RBC phenotyping in recently 
transfused patients, the relevant questions are, is there an 
antigen-negative RBC population, and, if so, could this be of 
recipient origin, taking into consideration the patient’s weight 
and Hct, the number of RBC units transfused, and the time 
after transfusion? Furthermore, mixed populations of RBCs 
are easily distinguishable with gel agglutination methods.
When considering patient RBC phenotyping after 
transfusion, these factors should be taken into account. 
Information on antigen doses in transfused units will usually 
be unavailable; however, in many instances and with many of 
the clinically significant RBC antigens, RBCs are more likely 
to have a single rather than double dose of the antigen. Studies 
with other antigens, test systems, and antisera, as well as in 
real patients, will be useful.
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